Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Mehr anzeigen
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data...
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0294 | -14.3135345667 | 0.2054 | 0.2389 | 0.1667 | 2408115 | 0.19973105 | CS |
| 4 | -0.019 | -9.74358974359 | 0.195 | 0.257406 | 0.146 | 2513310 | 0.19533475 | CS |
| 12 | -0.0538 | -23.4116623151 | 0.2298 | 0.2972 | 0.1315 | 3035514 | 0.19213174 | CS |
| 26 | -0.364 | -67.4074074074 | 0.54 | 0.58 | 0.1315 | 1683897 | 0.22015707 | CS |
| 52 | -0.4442 | -71.6220574008 | 0.6202 | 1.31 | 0.1315 | 896272 | 0.25079703 | CS |
| 156 | -2.994 | -94.4479495268 | 3.17 | 5.75 | 0.1315 | 415101 | 0.85494165 | CS |
| 260 | -16.584 | -98.9498806683 | 16.76 | 18.24 | 0.1315 | 383130 | 2.19939558 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
